Ginde Adit A, Cagliero Enrico, Nathan David M, Camargo Carlos A
Department of Emergency Medicine, University of Colorado Denver School of Medicine, Aurora, CO 80045, USA.
J Gen Intern Med. 2008 Sep;23(9):1346-53. doi: 10.1007/s11606-008-0661-6. Epub 2008 Jun 10.
Opportunistic screening using hemoglobin A1c (HbA1c) may improve detection of undiagnosed diabetes but remains controversial.
To evaluate the predictive validity of HbA1c as a screening test for undiagnosed diabetes in a risk-stratified sample of the US population.
Weighted cross-sectional analysis of diabetes risk factors, HbA1c, and fasting plasma glucose (FPG) in National Health and Nutrition Examination Survey (NHANES), 1999-2004.
Six thousand seven hundred and twenty-three NHANES participants from morning examination session, aged > or = 18 years and without prior physician-diagnosed diabetes.
HbA1c and undiagnosed diabetes defined by FPG > or = 7.0 mmol/l (126 mg/dl).
The estimated prevalence of undiagnosed diabetes in the US population was 2.8% (5.5 million people). HbA1c had strong correlation with undiagnosed diabetes, with an area under the receiver-operating characteristic curve of 0.93. Independent predictors of undiagnosed diabetes were older age, male sex, black race, hypertension, elevated waist circumference, elevated triglycerides, and low high-density lipoprotein cholesterol. We derived a risk score for undiagnosed diabetes and stratified participants into low (0.44% prevalence), moderate (4.1% prevalence), and high (11.1% prevalence) risk subgroups. In moderate and high risk groups, a threshold HbA1c value > or = 6.1% identified patients requiring confirmatory FPG; HbA1c < or = 5.4% identified patients for whom diabetes could be reliably excluded. Intermediate HbA1c (5.5-6.0%) may exclude diabetes in moderate, but not high risk groups).
Risk stratification improves the predictive validity of HbA1c in screening for undiagnosed diabetes in the US population. Although opportunistic screening with HbA1c would improve detection of undiagnosed diabetes, cost-effectiveness studies are needed before implementation of specific screening strategies using HbA1c.
使用糖化血红蛋白(HbA1c)进行机会性筛查可能会改善未诊断糖尿病的检测,但仍存在争议。
评估HbA1c作为美国人群风险分层样本中未诊断糖尿病筛查试验的预测有效性。
对1999 - 2004年国家健康和营养检查调查(NHANES)中的糖尿病风险因素、HbA1c和空腹血糖(FPG)进行加权横断面分析。
6723名来自NHANES上午检查时段的参与者,年龄≥18岁且既往无医生诊断的糖尿病。
HbA1c和根据空腹血糖≥7.0 mmol/l(126 mg/dl)定义的未诊断糖尿病。
美国人群中未诊断糖尿病的估计患病率为2.8%(550万人)。HbA1c与未诊断糖尿病有很强的相关性,受试者工作特征曲线下面积为0.93。未诊断糖尿病的独立预测因素为年龄较大、男性、黑人种族、高血压、腰围增加、甘油三酯升高和高密度脂蛋白胆固醇降低。我们得出了未诊断糖尿病的风险评分,并将参与者分为低风险(患病率0.44%)、中度风险(患病率4.1%)和高风险(患病率11.1%)亚组。在中度和高风险组中,HbA1c阈值≥6.1%可识别需要进行空腹血糖确认的患者;HbA1c≤5.4%可识别可可靠排除糖尿病的患者。中间HbA1c水平(5.5 - 6.0%)可在中度风险组而非高风险组中排除糖尿病。
风险分层提高了HbA1c在美国人群未诊断糖尿病筛查中的预测有效性。虽然使用HbA1c进行机会性筛查会改善未诊断糖尿病的检测,但在实施使用HbA1c的特定筛查策略之前,需要进行成本效益研究。